A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
- Conditions
- System Lupus Erythematosus
- Interventions
- Biological: SCTB35 injection
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06841042
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Xuanwu Hospital, Capital Medical University, Beijing, China
🇨🇳Jilin Provincial People's Hospital, Changchun, China
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine
- Conditions
- Herpes Zoster
- Interventions
- Biological: Recombinant Herpes Zoster Vaccine (SCTV04C) Low-DoseBiological: Ganwei®Biological: Recombinant Herpes Zoster Vaccine (SCTV04C) High-DoseBiological: Shingrix®
- First Posted Date
- 2025-01-30
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 540
- Registration Number
- NCT06801509
- Locations
- 🇨🇳
Dazhu CDC, Dazhou, Sichuan, China
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT06774664
- Locations
- 🇨🇳
The First Affiliated Hospital of Baotou Medical College, Baotou, China
🇨🇳Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
🇨🇳The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China
A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06769984
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Biological: Placebo
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT06754605
- Locations
- 🇨🇳
Hebei Zhongshiyou Central Hospital, Langfang, Hebei, China
🇨🇳Luzhou Center for Disease Control and Prevention, Luzhou, Sichuan, China
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients with NAMD (phase I Portion)
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06672536
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 441
- Registration Number
- NCT06600022
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma, B-cell
- Interventions
- Drug: SCTB35 injection
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT06318884
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 515
- Registration Number
- NCT06304818
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
- Conditions
- Relapsed or Refractory Hematologic Malignancies
- Interventions
- Biological: SCTC21C
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT06252298
- Locations
- 🇨🇳
Beijing Chaoyang Hospital ,Capital Medical University, Beijing, Beijing, China